Kezar Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc.?(Nasdaq:?KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced that it intends to offer and sell shares of its common stock and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering. All of the securities in the offering will be sold by Kezar. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Click to view original post